Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Plos One|August 10, 2022
Assessing the use of a micro-sampling device for measuring blood protein levels in healthy subjects and COVID-19 patientsJoost Brandsma, Josh G Chenoweth, Melissa K Gregory, et al.
Vaccine|September 2, 2022
First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adultsJack N Hutter, Paul M Robben, Christine Lee, et al.
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
Plos Pathogens|December 16, 2014
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAlexandra Schuetz, Claire Deleage, Irini Sereti, et al.
Plos One|January 26, 2013
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialSusan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, et al.
The Journal of Infectious Diseases|March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy TrialSupachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
The Journal of Infectious Diseases|October 3, 2017
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR BoostJulie A Ake, Alexandra Schuetz, Poonam Pegu, et al.
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Pageof 3